Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the ...

Data presented today at the ESHRE congress builds evidence for conventional-based Follicular Stimulating Hormone (FSH) dosing for Rekovelle (follitropin delta); alongside its existing unique algorithm ...

After decades of research, the U.S. Food and Drug Administration (FDA) has approved a test that can detect the buildup of amyloid plaques in the brain—a key marker of Alzheimer’s disease, ...

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

The US Food and Drug Administration (FDA) has expanded the indications of an imaging agent developed by GE HealthCare, which will likely put it at the forefront of the Alzheimer’s diagnostics arena.

The Lumipulse pTau 217/ β-Amyloid 1-42 Plasma Ratio test uses Fujirebio’s fully automated LUMIPULSE ® G1200 instrument system, which is widely available in clinical laboratories throughout the ...

This initiative follows the landmark FDA clearance of the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test developed by Fujirebio Diagnostics in May 2025.

NEW YORK, June 15, 2025 /PRNewswire/ -- It is with deep sorrow and profound admiration that the Alzheimer's Drug Discovery Foundation (ADDF) shares the passing of Co-Founder and Chairman, Leonard ...

One aliquot was used for pTau217 measurement using commercial kits on the Lumipulse G1200 as reported. 22 Another aliquot was used for pTau181, Aβ42, Aβ40, and ApoE4 measurement using the Elecsys® RUO ...

The firm's Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio is used for the measurement of pTau217 and β-amyloid 1-42 levels and calculation of the ratio between the proteins to aid the detection of ...

The test — called the "Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio" — is intended for people ages 55 and older who show signs and symptoms of cognitive decline that have been confirmed by ...